Prenatal exposure to endocrine disrupting chemicals in relation to thyroid hormone levels in infants – a Dutch prospective cohort study

Marijke de Cock1*, Michiel R de Boer1, Marja Lamoree2, Juliette Legler2 and Margot van de Bor1

Abstract

Background: Endocrine disrupting chemicals (EDCs) present in the environment may disrupt thyroid hormones, which in early life are essential for brain development. Observational studies regarding this topic are still limited, however as the presence of chemicals in the environment is ubiquitous, further research is warranted. The objective of the current study was to assess the association between exposure markers of various EDCs and thyroxine (T4) levels in newborns in a mother-child cohort in the Netherlands.

Methods: Exposure to dichlorodiphenyldichloroethylene (DDE), three di-2-ethylhexyl phthalate (DEHP) metabolites, hexachlorobenzene (HCB), polychlorinated biphenyl (PCB)-153, perfluorooctanesulfonic acid (PFOS), and perfluorooctanoic acid (PFOA) was determined in cord plasma or breast milk, and information on T4 levels in heel prick blood spots was obtained through the neonatal screening programme in the Netherlands. Linear regression models were composed to determine associations between each of the compounds and T4, which were stratified for gender and adjusted for a priori defined covariates.

Results: Mean T4 level was 86.9 nmol/L (n = 83). Girls in the highest quartile of DDE and PFOA exposure showed an increased T4 level compared to the lowest quartile with both crude and fully adjusted models (DDE > 107.50 ng/L, +24.8 nmol/L, 95% CI 0.79, 48.75; PFOA > 1200 ng/L, +38.6 nmol/L, 95% CI 13.34, 63.83). In boys a lower T4 level was seen in the second quartile of exposure for both PFOS and PFOA, however after fully adjusting the models these associations were attenuated. No effects were observed for the other compounds.

Conclusion: DDE and perfluorinated alkyl acids may be associated with T4 in a sex-specific manner. These results should however be interpreted with caution, due to the relatively small study population. More research is warranted, as studies on the role of environmental contaminants in this area are still limited.

Keywords: Endocrine disruptors, Fetal basis of adult disease, Thyroxine, Prenatal exposure

Background

Thyroid hormones (TH) play a significant role during development, both during the fetal period as well as after birth. They are essential for neurodevelopment as they regulate genes involved in neuronal cell differentiation and myelination [1]. Abnormal TH homeostasis early in life therefore may have long-term consequences. Congenital hypothyroidism is the most common cause of mental retardation and is associated with amongst others high birth weight, deafness, and spasticity [2,3]. Even small changes in maternal thyroid hormones may affect brain development, as maternal thyroid stimulating hormone (TSH) is inversely associated with offspring IQ [4]. Also other outcomes related to thyroid function, such as birth weight, may be affected by changes in maternal thyroid hormone levels within the normal range [5].

Hormones, including thyroid hormones, are sensitive to external factors such as chemicals which are present...
in the environment. Exposure to endocrine disrupting chemicals (EDCs) such as polybrominated diphenyl ethers (PBDEs), polychlorinated biphenyls (PCBs) and perfluorinated alkyl acids (PFAAs) have been associated with effects on TH homeostasis. Prenatal exposure to PBDE mixture DE-71 in rats has been associated with reduced T4 levels in both males and females [6,7]. Male rats prenatally exposed to PBDE and polychlorinated biphenyls (PCBs), either as a single compound or as a mixture, also showed reduced T4 levels [8,9]. Similar results were observed in prenatally exposed female rats [10]. Also gestational perfluoroctanesulfonic acid (PFOS) exposure was associated with reduced T4 levels in rats [11,12]. Human studies on prenatal environmental exposures and thyroid hormones, and T4 in particular, are still scarce. Prenatal exposure to BDE-100 measured in cord blood of Taiwanese newborns was associated with an increase in thyroxine/3,5,3'-triiodothyronine (T4/T3) ratio [13], and also for BDE-154 measured in breast milk a positive correlation with cord blood log T4 was observed [14]. However, for BDE-99 a decrease in free T4 (fT4) levels was reported in the same study. Furthermore Kim et al. [15] observed that cord blood PFOS and perfluoroctanoic acid (PFOA) exposure were negatively associated with cord blood T4 levels [15]. However after adjusting the models for covariates, most relationships lost significance. Also Darnerud et al. who looked at early life exposure to PCBs and DDE in breast milk observed no associations with thyroid hormones in a population of Swedish newborns [16].

Results from previous studies are not consistent, and as neonatal TH levels may depend on various factors such as birth weight, gestational age, and mode of delivery, it is important to consider the timing of sampling [17]. Neonatal screening programs use heel prick blood spots sampled several days after birth, which is advantageous compared to e.g. cord blood as TH levels may be less affected by stress of the delivery [18]. The objective of this study was therefore to assess the association between exposure markers of various chemicals determined in cord blood and T4 levels determined as part of the national neonatal screening programme. For this purpose data from a newly established mother-child cohort in the Netherlands was used: the LINC study (Linking EDCs in maternal nutrition to child health). The compounds included were dichlorodiphenyldichloroethylene (DDE), polychlorinated biphenyl (PCB)-153, and hexachlorobenzene (HCB), of which health effects have been studied frequently, as well as some relatively ‘new’ compounds: metabolites of di(2-ethylhexyl) phthalate (DEHP), including mono(2-ethyl-5-carboxypentyl) phthalate (MECPP), mono(2-ethyl-5-hydroxyhexyl) phthalate (MEHHP), and mono(2-ethyl-5-oxohexyl) phthalate (MEOHP), as well as PFOS, and PFOA.

Materials and methods

Study procedures and subjects

Participants from the LINC study were recruited between January 2011 and January 2013, through six midwifery clinics in the area of Zwolle in the Netherlands. The community Zwolle is located in the ‘Salland’ area, which is characterized by agriculture and stock-breeding and a relatively low level of urbanization. As only one hospital is available to serve this community, child births were relatively easy to track. Women were invited to participate during the first antenatal visit to the midwife and were considered eligible for participation if they were able to fill out Dutch questionnaires. Twin pregnancies and major congenital anomalies were reasons for exclusion, however no participant was excluded because of these criteria. Signed informed consent was obtained from every participant. Cord blood and breast milk were collected for determination of markers of exposure to several endocrine disrupting chemicals. The national neonatal screening programme was contacted for data on T4 measured in heel prick blood samples. Information on birth weight, gestational age, and parental anthropometry was obtained from the midwives, and questionnaires were administered during pregnancy to collect information on parental health and lifestyle, and previous pregnancies. The study was approved by the medical ethics committee of the VU University medical centre in Amsterdam.

Thyroxine

The National Institute for Public Health and the Environment was approached in order to obtain data on T4 as measured in the neonatal screening programme. Permission from the parents was ascertained for this specific part of the study. Blood samples were collected on filter paper through heel puncture which was performed on average between day 4 and day 7 after birth. Total T4 was determined by means of Autodelfia [19].

Chemical exposure

These methods have been previously published [20]. Umbilical cord blood was collected immediately after birth when the health of mother and child was ascertained. Midwifes and nurses were instructed to collect as much blood as possible in EDTA tubes through manual expression. The blood was delivered to the lab within twelve hours by a courier in case of home delivery or by someone from the hospital staff in case of delivery at the hospital. At the lab, cord blood was centrifuged for 10 minutes at 2000 g. after which the plasma layer was transferred to plasma tubes. Plasma was stored at −80°C.

Breast milk was collected in the second month after birth (mean [SD] weeks after birth: 6.3 [2.5]). In total a minimum of 100 mL. was collected, spread over five to
ten days to minimize the burden to the mothers in case of low milk flow. Mothers were instructed to note the dates on which they collected a sample and to store the milk in the freezer in between sampling days. They were allowed to use a breast pump for collection.

Compounds were analysed in cord plasma. For DDE and HCB we also analysed breast milk samples from mothers for whom an insufficient amount of cord blood was available. PFOA and PFOS were analysed by applying isotope dilution and large volume injection using an on-line trapping column coupled to liquid chromatography and triple quadrupole mass spectrometry. The breast milk samples were extracted with solid phase extraction using Oasis WAX cartridges. For the cord plasma samples, the proteins were precipitated by adding methanol and centrifuging the mixture prior to injection onto the analytical system.

After drying both the cord plasma and the breast milk samples with Kieselguhr, the organochlorine pesticides p,p'-DDE, HCB and PCB153 were extracted with a mixture of dichloromethane and hexane. Cleanup of the extracts was done using sulphuric acid silica columns and for the analysis gas chromatography with mass spectrometric detection in negative chemical ionization mode was used.

Di-2-ethylhexyl phthalate (DEHP) exposure was analysed by analysis of three secondary metabolites mono (2-ethyl-5-carboxypentyl) phthalate (MECPP), mono(2-ethyl-5-hydroxyhexyl) phthalate (MEHHP), and mono (2-ethyl-5-oxohexyl) phthalate (MEOHP). Enzymatic deconjugation was carried out, and after addition of the internal standards used for isotope dilution, the breast milk samples were extracted using Oasis MAX cartridges, while for the cord plasma samples a simple protein precipitation step using formic acid was applied. The extracts were analysed after large volume injection using an online trapping column coupled to liquid chromatography and triple quadrupole mass spectrometry. Problems due to the occurrence of contamination of the breast milk samples are to be expected for mono(2-ethylhexyl) phthalate (MEHP), the hydrolytic monoester of DEHP, that has shown to also be formed in the matrix due to the residual activity of enzymes (lipases, esterases), even after prolonged storage periods at −20°C. Therefore, MEHP is a very unreliable parameter for the assessment of DEHP exposure and should not be used for breast milk. In contrast, MECPP, MEHHP, and MEOHP are not susceptible to contamination as they are major metabolites of DEHP created by the liver. They are only formed in vivo and serve as a reliable parameter for DEHP exposure.

The coefficient of variation for the chemicals measured, was 16 – 17%. More information on chemical analysis, including limits of quantification and quality control parameters, is given in Additional file 1, p. 2–4.

Covariates
Covariates were selected based on literature [5,21-25]. Each participant was asked for thyroid gland related health problems (yes or no) and use of related medication during pregnancy (yes or no), by means of questionnaire.

Birth weight was measured after birth by a midwife or a nurse and data were subsequently obtained from registries of the midwives. Newborns were put on the weighing scale without a diaper and birth weight was determined when the infant was in a calm state. Weighing scales were provided by the midwife and were calibrated daily.

Weight and length of the mother and father were measured by the midwife at inclusion, approximately 10–12 weeks in pregnancy. Measurement of maternal weight was repeated at 36 weeks in pregnancy to determine gestational weight gain. Midwives received strict instructions on how to perform these measurements as well as a measuring tape which was attached to a wall in the midwife’s office. Weighing scales were provided by the midwife and were calibrated daily. Gestational age was determined by midwives by means of ultrasound. Mode of delivery (caesarean section, yes or no) was recorded by the midwife.

Questionnaires were administered to collect information on birth date of the mother, parity, maternal smoking during the first trimester (yes or no), and alcohol intake during the first trimester (drinks per week).

Data-analysis
Data analysis was performed using SPSS version 20 [26]. Separate linear regression models were composed for each compound. To take into account gender-specific effects of exposure, models were stratified for gender by means of interaction terms which were added to the models. For each compound exposure values below the limit of quantification (LOQ) were replaced by LOQ/√2 [27]. As DDE accumulates in lipid, the following conversion factor was used to transform levels in breast milk to levels in cord blood [27].

\[
[DDE, \text{cord plasma (ng/L)}] = 1.20 \times [DDE, \text{breast milk (ng/g lipid)}]
\]

The conversion factor for DDE was based on what has been published for other European cohorts. For PCB-153 measured in cord plasma, over 50% of the samples had an exposure level that was below LOQ. As PCB-153 was determined predominantly in cord blood it was decided to include PCB-153 as a dichotomous variable (>LOQ vs. <LOQ). None of the compounds showed a linear association with T4 levels, therefore each exposure was split up in quartiles and included as dummy variables in the model. Models were initially adjusted for health problems related to the thyroid gland, use of
thyroid medication, birth weight, and caesarean section. Fully adjusted models also included gestational weight gain, gestational age, parity, smoking, alcohol, maternal BMI, and maternal age at birth. Each of these covariates was checked for linearity with T4 and was included in the models regardless of the degree of confounding. As gestational weight gain is mostly seen as a confounder for lipophilic compounds, and as birth weight is considered to be associated with maternal thyroid hormones, we performed sensitivity analyses for these variables by excluding them from the models. The distribution of T4 was checked for normality and outliers by means of histograms. For each model the residuals were plotted and checked as well for normal distribution. Effect modification by smoking was also taken into consideration and was included if the interaction term was significant (p < 0.05).

Results
In total 148 women were included, of whom 14 subjects dropped-out. Due to failed sample collection or insufficient sample volumes, exposure data were not available for an additional 51 children, resulting in the inclusion of 83 mother-child pairs for analysis. A description of the LINC study population is presented in Table 1. Mean T4 level was 85.6 nmol/L in boys and 89.6 nmol/L in girls, and mean birth weight was 3632 and 3546 grams in boys and girls respectively. Caesarean section was performed in 2.4% of births, and maternal thyroid disease as well as use of related medication was reported by one participant.

An overview of exposure levels of various compounds in cord plasma as well as breast milk is given in Table 2. For PCB-153, DDE, and HCB, wet weight levels in breast milk were significantly higher than in cord plasma. However, lipid adjusted levels were similar, reflecting the high fat content of the breast milk. For these compounds the percentage of samples with exposure levels above the LOQ was also higher in breast milk than in cord blood. Concentrations of HCB in cord blood were < LOQ in more than 98% of the samples. Therefore HCB was not included in the analysis.

All three DEHP metabolites as well as the PFAAs had relatively high quantification rates. In contrast to what was observed for PCB-153, DDE, and HCB, levels of PFOS and PFOA were higher in cord plasma compared to breast milk.

Associations with T4 were observed for total DDE, PFOS, and PFOA, depending on the sex of the infant (Tables 3 and 4). Girls in the highest quartile of total DDE exposure showed significantly increased T4 levels compared to the lowest exposed group for crude as well as adjusted analyses, while for boys no difference in T4 levels were detected across quartiles. Boys in the second and third quartile of PFOS exposure had significantly lower T4 levels than the reference group with the crude model (respectively $-22.1$ nmol/L, 95% CI: $-38.75$ to $-5.48$; and $-16.8$ nmol/L, 95% CI $-33.47$ to $-0.21$). After partially adjusting the model, only the second quartile remained significantly lower than the reference group, but in the fully adjusted model also this association disappeared. In girls no effect of PFOS exposure on T4 levels was observed, however for PFOA the

| Table 1 Population characteristics (n = 83) |
|------------------------------------------|
| **Boys (n = 52)** | **Girls (n = 31)** |
|-------------------|-------------------|
| **T4 (nmol/L)**   | **Mean ± SD**     | **Mean ± SD**     |
|                   | **Mean ± SD**     | **Min - max**     | **Min - max** |
|                   | **Min - max**     | **Min - max**     |
|                   | 85.6 ± 20.0       | 42 - 138          | 89.6 ± 14.9   | 68 - 117 |
| Birth weight (g.) | 3632.1 ± 501.5    | 2130 - 4950       | 3546.3 ± 397.6| 2710 - 4350|
| Gestational age (weeks) | 39.7 ± 1.5       | 34.1 – 41.6       | 40.1 ± 1.0    | 36.6 – 42.0|
| Small for gestational age (n) | 3 (5.8%)         | 1 (3.3)           |                |            |
| Large for gestational age (n) | 5 (9.6)          | 2 (6.7)           |                |            |
| Parity (nulliparous, n) | 20 (40.0%)       | 0 – 4             | 10 (32.3%)    | 0 – 3     |
| Caesarean (yes, n)  | 2 (3.8%)         | -                 | 1 (3.3)       | -         |
| Thyroid disease (yes, n) | 0              | -                 | 1 (3.3)       | -         |
| BMI mother (start pregnancy, kg/m²) | 23.7 ± 3.4       | 17.8 – 32.5       | 23.0 ± 4.3    | 18.8 – 36.5 |
| Gestational weight gain (kg.) | 12.7 ± 4.2      | 1.0 – 23.0        | 12.1 ± 5.3    | -6.0 – 20.0 |
| Age mother (years) | 33.0 ± 4.9      | 23.0 – 40.0       | 32.0 ± 3.4    | 23 – 36   |
| Smoking (first trimester, yes, n) | 2 (3.8%)        | -                 | 2 (6.5%)      | -         |
| Alcohol (yes, n)  | 2 (3.8%)         | -                 | 2 (6.5%)      | -         |

*Values are mean ± SD unless stated otherwise.*
highest quartile of exposure showed increased T4 levels with the crude as well as the adjusted models. Mean T4 levels were 22.8 nmol/L (95% CI 0.86 to 44.79) higher compared to the reference group when no adjustments for covariates were made. This difference increased to 38.6 nmol/L (95% CI: 13.34 to 63.83) in the fully adjusted model. In boys no effect of PFOA exposure on T4 was observed, except for the second quartile of exposure, which had a significantly lower T4 level than the reference group (−20.3 nmol/L, 95% CI: −37.29 to −3.24). However, the adjusted analyses showed attenuated and even opposite associations that were no longer statistically significant. No significant associations with T4 were observed for the DEHP metabolites as well as for PCB-153 (Table 5). Removing birth weight or gestational weight gain from the models did not affect the results (not shown).

Discussion

The objective of the current study was to investigate the association between prenatal exposure to various endocrine disrupting chemicals measured in cord blood and breast milk, and T4 levels determined in heel prick blood spots. Girls in the highest quartile of DDE and PFOA exposure showed increased T4 levels compared to the lowest quartile, a difference which remained significant after fully adjusting the model for covariates. For PFOA, the highest exposed group of girls had a mean T4 level which was 38.6 nmol/L higher than the reference group, a difference which is quite large considering that the range in T4 values in this cohort was 96 nmol/L. In boys a lower T4 level was seen in the second quartile of exposure for both PFOS and PFOA, however after adjusting the models, these associations attenuated and were no longer significant. For the DEHP metabolites as well as for PCB no association with T4 was observed in either boys or girls.

The positive association between DDE exposure and T4 in the highest exposed quartile of girls is not in line with what has been reported in other observational studies [16,28,29], which either report no association or an inverse association. It should be noted that Maervoet et al. and Asawasinsopon et al. determined fT4 or T4 in cord blood, which may have confounded their results as

Table 2 Exposure levels in cord plasma and/or breast milk

| Compound | N   | Mean | Median | Range       | LOQ  | <LOQ (%) |
|----------|-----|------|--------|-------------|------|----------|
| PCB-153  |     |      |        |             |      |          |
| Cord plasma - ng/L | 51  | 35.40 | 28.28  | 22.63 – 96.00 | 21 – 43 | 57.7     |
| Cord plasma - ng/g lipid | 51  | 36.02 | 30.00  | 17.95 – 88.89 | 14 – 53 | 57.7     |
| DDE      |     |      |        |             |      |          |
| Cord plasma - ng/L | 51  | 114.48 | 79.00  | 37.48 – 470.00 | 33 – 73 | 23.1     |
| Cord plasma - ng/g lipid | 51  | 115.98 | 81.97  | 28.83 – 580.25 | 23 – 86 | 23.1     |
| Breast milk - ng/L | 24  | 2379.58 | 1895.00 | 400.00 – 11390.00 | 9.20 – 13.00 | 0        |
| Breast milk - ng/g lipid | 24  | 59.20 | 44.10  | 12.11 – 277.80 | 0.13 – 0.53 | 0        |
| HCB      |     |      |        |             |      |          |
| Cord plasma - ng/L | 51  | 44.33 | 44.55  | 28.28 – 78.00 | 40 – 79 | 98.1     |
| Cord plasma - ng/g lipid | 51  | 46.23 | 45.85  | 27.27 – 82.11 | 25 – 96 | 98.1     |
| Breast milk - ng/L | 24  | 622.92 | 655.00 | 300.00 – 1060.00 | 9.20 – 13.00 | 0        |
| Breast milk - ng/g lipid | 24  | 15.94 | 14.94  | 10.65 – 25.85 | 0.16 – 0.68 | 0        |
| MECCPP   |     |      |        |             |      |          |
| Cord plasma - ng/mL  | 64  | 0.31 | 0.27   | 0.11 – 1.00 | 0.13 – 0.28 | 7.8      |
| MEHHP    |     |      |        |             |      |          |
| Cord plasma - ng/mL  | 64  | 0.33 | 0.27   | 0.10 – 1.00 | 0.14 – 0.27 | 9.4      |
| MEOHPP   |     |      |        |             |      |          |
| Cord plasma - ng/mL  | 64  | 0.29 | 0.23   | 0.12 – 0.87 | 0.17 – 0.33 | 25.0     |
| PFOA     |     |      |        |             |      |          |
| Cord plasma - ng/L | 64  | 943.44 | 885    | 200 – 2700  | 50 – 140 | 0        |
| PFOS     |     |      |        |             |      |          |
| Cord plasma - ng/L | 64  | 1616.88 | 1600   | 570 – 3200  | 44 – 140 | 0        |

*For total DDE, cord plasma exposure data were merged with breast milk exposure levels converted to cord plasma levels.
cord blood is sampled directly after birth and T4 levels may have been elevated due to stress of the delivery (median total T4 level in the study of Asawasinsopon et al. was 111.3 nmol/L). Furthermore DDE levels were higher in both these cohorts (189 ng/g lipid and 742 ng/g lipid for Maervoet et al. and Asawasinsopon respectively). Also in animal studies disruption of TH by DDE is higher in both these cohorts (189 ng/g lipid and 742 ng/g lipid for Maervoet et al. and Asawasinsopon respectively). In the current study, women had significantly higher T4 levels than men across all specific interactions for PFOS, but not PFOA, and T4, and found both compounds to be associated with increased DDE levels. Kim et al. observed no associations between cord blood PFOS or PFOA concentrations and T4 or TSH in the newborn. Concentrations of exposures were similar to the current study, however analyses were not stratified for gender, which may explain discrepancies with our results. We observed that girls with a relatively high T4 level, which was significantly higher than their peers with low exposure. These gender dimorphic associations have also been seen by Knox et al. [35], who determined PFOS and PFOA in serum of adults. The differences in T4 levels for PFOA exposure in girls may have been elevated due to stress of the delivery (median total T4 level in the study of Asawasinsopon et al. was 111.3 nmol/L). Furthermore DDE levels were higher in both these cohorts (189 ng/g lipid and 742 ng/g lipid for Maervoet et al. and Asawasinsopon respectively). In the current study, women had significantly higher T4 levels than men across all specific interactions for PFOS, but not PFOA, and T4, and found both compounds to be associated with increased DDE levels. Kim et al. observed no associations between cord blood PFOS or PFOA concentrations and T4 or TSH in the newborn. Concentrations of exposures were similar to the current study, however analyses were not stratified for gender, which may explain discrepancies with our results. We observed that girls with a relatively high T4 level, which was significantly higher than their peers with low exposure. These gender dimorphic associations have also been seen by Knox et al. [35], who determined PFOS and PFOA in serum of adults and found both compounds to be associated with increases in serum T4 [35]. They furthermore observed gender specific interactions for PFOS, but not PFOA, and T4, with women having higher T4 levels than men across all quartiles of exposure.

The differences in T4 levels for PFOA exposure in girls are relevant as they may potentially have implications for

---

### Table 3 Regression coefficients for various exposures in boys (in quartiles) and T4 (nmol/L)

| Compound | Q1 (N) | Q2 (41.80 – 74.50) | Q3 (74.51 – 107.50) | Q4 (>107.50) |
|----------|--------|-------------------|-------------------|-----------|
| DDE (Total, ng/L) | <41.80 | 41.80 – 74.50 | 74.51 – 107.50 | >107.50 |
| Crude | 70 | Ref | –2.1 (−17.33, 13.23) | 0.789 | –8.5 (−23.51, 6.43) | 0.258 | 2.1 (−12.27, 16.42) | 0.773 |
| Model A | 65 | Ref | –3.3 (−20.00, 13.33) | 0.690 | –6.6 (−22.60, 9.31) | 0.407 | 2.8 (−12.05, 17.58) | 0.710 |
| Model B² | 61 | Ref | 10.5 (−13.94, 34.90) | 0.389 | 2.9 (−17.00, 22.71) | 0.771 | 8.0 (−10.68, 26.77) | 0.389 |
| MEHHP (ng/mL) | <0.22 | 0.22 – 0.27 | 0.28 – 0.38 | >0.38 |
| Crude | 63 | Ref | –1.8 (−18.34, 14.65) | 0.823 | –4.9 (−21.73, 12.00) | 0.565 | 9.3 (−7.97, 26.63) | 0.284 |
| Model A | 57 | Ref | –3.2 (−20.11, 14.61) | 0.719 | –6.8 (−25.19, 11.50) | 0.456 | 9.6 (−9.30, 28.56) | 0.311 |
| Model B² | 52 | Ref | –18.2 (−37.96, 1.62) | 0.070 | –12.3 (−34.98, 10.37) | 0.257 | –4.2 (−26.88, 18.51) | 0.708 |
| MEHEHP (mg/mL) | <0.18 | 0.18 – 0.27 | 0.28 – 0.39 | >0.39 |
| Crude | 63 | Ref | –4.0 (−21.73, 13.73) | 0.653 | –3.1 (−22.87, 16.77) | 0.758 | 2.7 (−16.20, 21.54) | 0.777 |
| Model A | 57 | Ref | –1.9 (−21.06, 17.23) | 0.841 | –1.7 (−22.42, 19.11) | 0.873 | 7.8 (−12.74, 28.36) | 0.448 |
| Model B² | 52 | Ref | –2.4 (−26.23, 21.51) | 0.841 | 1.3 (−24.08, 26.60) | 0.919 | 4.6 (−22.28, 31.50) | 0.728 |
| MEOHP (mg/mL) | <0.17 | 0.17 – 0.23 | 0.24 – 0.41 | >0.41 |
| Crude | 63 | Ref | 15.2 (−2.37, 32.71) | 0.089 | 8.8 (−9.37, 26.97) | 0.336 | 12.2 (−5.97, 30.37) | 0.184 |
| Model A | 57 | Ref | 13.6 (−4.66, 31.95) | 0.140 | 7.9 (−10.50, 26.30) | 0.392 | 15.9 (−2.98, 34.75) | 0.997 |
| Model B² | 52 | Ref | 3.8 (−19.48, 27.16) | 0.738 | −6.1 (−31.51, 19.31) | 0.626 | −1.8 (−26.20, 22.58) | 0.880 |
| PFOS (ng/L) | <1026 | 1026 – 1600 | 1601 – 2175 | >2175 |
| Crude | 62 | Ref | −22.1 (−38.75, −5.48) | 0.010 | −16.8 (−33.47, −0.21) | 0.047 | −11.8 (−29.14, 5.64) | 0.181 |
| Model A | 57 | Ref | −22.8 (−39.83, −5.83) | 0.010 | −18.0 (−36.84, 0.79) | 0.060 | −13.9 (−31.56, 3.81) | 0.121 |
| Model B² | 52 | Ref | −7.9 (−31.56, 15.74) | 0.499 | −16.5 (−40.32, 7.34) | 0.167 | −9.6 (−32.57, 13.31) | 0.396 |
| PFOA (ng/L) | <591 | 591 – 865 | 866 – 1200 | >1200 |
| Crude | 62 | Ref | −20.3 (−37.29, −3.24) | 0.021 | −12.2 (−27.15, 2.80) | 0.109 | −11.3 (−28.29, 5.80) | 0.190 |
| Model A | 57 | Ref | −16.8 (−35.09, 1.54) | 0.072 | −7.7 (−23.93, 8.46) | 0.341 | −9.2 (−27.09, 8.79) | 0.310 |
| Model B² | 52 | Ref | 7.9 (−18.04, 33.92) | 0.536 | −2.1 (−20.94, 16.78) | 0.823 | 6.2 (−16.08, 28.50) | 0.572 |

1Adjusted for thyroid gland problems, use of thyroid medication, and birth weight. Caesarean section was constant and not included in the model.

2Model A + additionally adjusted for gestational weight gain, gestational age, parity, smoking, alcohol, maternal BMI, and maternal age at birth.

*p < 0.050.
Table 4 Regression coefficients for various exposures in girls (in quartiles) and T4 (nmol/L)

| Compound (Total, ng/L) | n | Q1 (β, 95% CI) | p-value | Q2 (β, 95% CI) | p-value | Q3 (β, 95% CI) | p-value | Q4 (β, 95% CI) | p-value |
|------------------------|---|----------------|---------|----------------|---------|----------------|---------|----------------|---------|
| DDE (Total, ng/L)      |   | 41.80 – 74.50  |         | 74.51 – 107.50 |         | >107.50        |         | <0.05          |         |
| Crude                  | 70 | Ref. 0.7 (−16.17, 17.48) | 0.938 | 3.9 (−14.66, 22.47) | 0.675 | 20.2 (1.59, 38.71) | 0.034 |         |         |
| Model A                 | 65 | Ref. 3.0 (−14.66, 20.69) | 0.734 | 2.3 (−17.14, 21.80) | 0.811 | 24.4 (2.30, 46.47) | 0.031 |         |         |
| Model B                 | 61 | Ref. 8.7 (−10.00, 27.45) | 0.350 | 8.6 (−13.00, 30.18) | 0.424 | 24.8 (0.79, 48.75) | 0.043 |         |         |
| MEHP (ng/mL)           | <0.17 | 0.22 – 0.27  | <0.18 | 0.28 – 0.38       |         | >0.38          |         |         |         |
| Crude                  | 63 | Ref. −1.6 (−22.55, 19.93) | 0.877 | −12.0 (−36.62, 12.62) | 0.333 | 11.3 (−13.37, 35.87) | 0.363 |         |         |
| Model A                 | 57 | Ref. 3.4 (−18.62, 25.37) | 0.759 | −10.3 (−38.03, 17.52) | 0.461 | 16.3 (−11.69, 44.36) | 0.247 |         |         |
| Model B                 | 52 | Ref. 6.2 (−24.71, 37.04) | 0.685 | −14.5 (−45.49, 16.44) | 0.344 | 14.0 (−14.01, 42.07) | 0.314 |         |         |
| MEOHP (ng/mL)          | <0.17 | 0.18 – 0.27  | <0.18 | 0.28 – 0.39       |         | >0.39          |         |         |         |
| Crude                  | 63 | Ref. −9.3 (−34.00, 15.47) | 0.456 | −8.0 (−28.68, 12.68) | 0.441 | −3.2 (−30.24, 23.91) | 0.815 |         |         |
| Model A                 | 57 | Ref. −7.8 (−35.52, 20.00) | 0.575 | −8.1 (−29.95, 13.66) | 0.456 | −1.5 (−29.50, 26.41) | 0.912 |         |         |
| Model B                 | 52 | Ref. −5.7 (−49.41, 38.11) | 0.793 | −11.2 (−35.27, 12.94) | 0.350 | −0.4 (−30.20, 29.43) | 0.979 |         |         |
| PFOS (ng/L)            | <1026 | 1026 – 1600  |         | 1601 – 2175       |         | >2175          |         |         |         |
| Crude                  | 62 | Ref. −3.3 (−24.28, 17.65) | 0.752 | −2.7 (−27.42, 22.00) | 0.826 | 9.5 (−10.46, 29.37) | 0.345 |         |         |
| Model A                 | 57 | Ref. 2.3 (−36.53, 10.91) | 0.283 | 2.5 (−30.01, 34.94) | 0.879 | −9.7 (−32.80, 13.37) | 0.401 |         |         |
| Model B                 | 52 | Ref. −19.6 (−47.55, 8.30) | 0.161 | 1.6 (−35.19, 38.30) | 0.932 | −12.5 (−40.01, 19.92) | 0.357 |         |         |
| PFOA (ng/L)            | <591 | 591 – 865   |         | 866 – 1200       |         | >1200          |         |         |         |
| Crude                  | 62 | Ref. −3.6 (−23.09, 15.90) | 0.713 | 2.6 (−19.40, 24.54) | 0.815 | 22.8 (0.86, 44.79) | 0.042 |         |         |
| Model A                 | 57 | Ref. −1.5 (−22.39, 19.40) | 0.886 | 11.3 (−14.23, 36.79) | 0.378 | 27.8 (5.03, 50.64) | 0.018 |         |         |
| Model B                 | 52 | Ref. −5.9 (−26.75, 14.94) | 0.566 | 11.8 (−19.08, 42.72) | 0.439 | 38.6 (13.34, 63.83) | 0.004 |         |         |

1Adjusted for thyroid gland problems, use of thyroid medication, and birth weight. Caesarean section was constant and not included in the model.
2Model A + additionally adjusted for gestational weight gain, gestational age, parity, smoking, alcohol, maternal BMI, and maternal age at birth.

Table 5 Regression coefficients for PCB-153 (<LOQ vs. >LOQ) and T4 (nmol/L), stratified for gender

| N | <LOQ | >LOQ | β (95% CI) | P-value |
|---|------|------|------------|---------|
| Male | Crude | 48 | Ref. | 3.3 (−9.58, 16.20) | 0.607 |
|     | Model A | 45 | Ref. | 4.2 (−9.63, 18.05) | 0.542 |
|     | Model B | 42 | Ref. | −0.6 (−19.02, 17.79) | 0.945 |
| Female | Crude | 48 | Ref. | −4.5 (−22.54, 13.55) | 0.618 |
|      | Model A | 45 | Ref. | −7.4 (−28.59, 13.78) | 0.483 |
|      | Model B | 42 | Ref. | −17.2 (−43.52, 9.04) | 0.188 |

1Adjusted for thyroid gland problems, use of thyroid medication, and birth weight. Caesarean section was constant and not included in the model.
2Model A + additionally adjusted for gestational weight gain, gestational age, parity, smoking, alcohol, maternal BMI, and maternal age at birth.

Their health later in life. In a Spanish cohort, low free T4 and high TSH levels within the normal range were associated with symptoms of attention deficit hyperactivity disorder (ADHD) in four year olds [36]. A similar observation was made in subjects with resistance to thyroid hormone, in whom total T4 concentrations correlated positively with symptoms of hyperactivity [37]. Though the study by Alvarez-Pedrerol et al. was a cross-sectional study, the association between symptoms of ADHD and thyroid hormones in the normal range may be an indication of the sensitivity of the process of neurodevelopment at young age. None of the subjects in the current study had deviating or dubious T4 levels according to the cut-offs used in the Dutch neonatal screening program [38]. It would be interesting to follow these children up at later age to see if there is a relation between early life exposure and prevalence of neurodevelopmental disorders, and if so, if these associations are mediated by thyroid hormones.
It has been shown in experimental studies that PFAAs may displace T4 from binding proteins such as albumin [39-41] or transthyretin [42], which would result in an increase in fT4 and a subsequent decrease in T4, opposite from our observations. This has been however predominantly shown in vitro. In vivo studies are few, and it has furthermore been suggested that animals react differently to endocrine disrupting chemicals, either having a higher tolerance [43], as well as having a TH status more sensitive to exogenous compounds [44]. It would therefore be very interesting to measure both T4 and thyroid binding proteins in humans, however this information was not available in the current study. Further research is required to elucidate how PFAAs interact with thyroid hormones.

Data within this cohort was collected prospectively, and though small, this study population was very homogenous as all women were of Dutch origin and the majority was high educated (64% having a bachelor or master degree). Associations are therefore less likely to be confounded by demographic or socio-economic factors. Covariates were carefully selected based on literature, however the association between fetal T4 and gestational weight gain has not been reported on frequently, which might make inclusion of this variable in the models questionable. However in a recently published study by Pop et al. [25], fetal fT4 concentrations were associated with high weight gain during pregnancy [45]. Furthermore Verner et al. [46] reported that gestational weight gain is associated with lipophilic compounds in particular, implying that it should be considered as a potential confounder. Also birth weight was included as a covariate, however associations between birth weight and thyroid hormones have mainly been reported for maternal as opposed to offspring thyroid hormones. We therefore performed sensitivity analysis by excluding both variables independently from the models, which did not affect results. We furthermore did not adjust our analysis for time separately from the models, which did not affect re-performed sensitivity analysis by excluding both variables as opposed to offspring thyroid hormones. We therefore know of for gender-specific effects regarding disruption of thyroid hormones, our results only showed effects for girls. As the standard errors of the models were not affected after stratification, it was decided to present results separately for boys and girls. We have not used corrections for multiple testing, such as a Bonferroni correction, because this would further reduce the power of our statistical tests, but we are aware that some of the findings may be false positive findings.

The small sample size was partly due to 51 participants for whom no samples or insufficient volumes of cord blood were available. Most of the participants gave birth at home, and collection of cord blood was not always possible due to emergency transport to the hospital where the participants were referred to the obstetrician, or errors occurred in transport of samples to the laboratory. For some participants no breast milk was available, as not all children received breast feeding.

DDE levels determined in milk samples, approximately one third of samples, were converted to cord blood values by means of a factor derived from what has been previously published in a meta-analysis of twelve birth cohorts. Though there is no standard conversion factor, we considered this the best option as it was based on cohorts from Europe. Nonetheless, it may have attenuated associations.

No associations between PCB-153 and T4 were observed in both boys and girls. This was in line with a similar study in a Canadian birth cohort, despite their relatively high exposure to this compound [48]. On the other hand, an inverse association between fT4 and PCB-153 was reported for a Belgian cohort, in which exposure levels were comparable to levels in our study population [28]. It must be noted that for both the Belgian and the Canadian cohort, thyroid hormones were determined in cord blood, and comparison of results for PCB-153 is therefore complicated. Also for each of the DEHP metabolites no effects on T4 were observed. Exposure was determined in cord blood and breast milk, which is relatively novel as in most studies urine is used. We were able to quantify levels in the majority of the samples, as the LOQ was very sensitive and in some samples as low as 0.13 ng/mL, compared to a limit of detection of 0.2 ng/mL which was for example reported by Olsén et al. who determined DEHP metabolites in serum of elderly people in Sweden [49]. Though there are several studies in adults, only one study is available which related serum T4 levels to phthalate levels in urine of four to nine year old children [50]. No effect of exposure on T4 was reported, however, various phthalates showed a positive association with levels of free and total T3, indicating that phthalates may potentially also interact with TH. Experimental evidence for
this is however insufficient. As application of phthalates is widespread, future studies should aim to include these compounds when investigating the effect of environmental exposures on thyroid function.

Conclusions
This study showed that DDE and PFAAs may be associated with T4 in a sex-specific manner. The study population was relatively small, therefore results should be interpreted with caution, and confirmation from larger studies is warranted. Thyroid hormones are very important during developmental stages in life, and even subtle changes may have an impact on child health. More research is warranted, as studies on the role of environmental contaminants in this area are still limited.

Additional file

Additional file 1: Prenatal exposure to endocrine disrupting chemicals in relation to thyroid hormone levels in infants.

Abbreviations
BMI: Body mass index; DDE: Dichlorodiphenyldichloroethylene; DEHP: Di-2-ethylhexyl phthalate; EDCs: Endocrine disrupting chemicals; fT4: Free thyroxine; HCB: Hexachlorobenzene; LOQ: Limit of quantification; MECPP: Mono(2-ethyl-5-carboxypentyl)phthalate; MEHHP: Mono(2-ethyl-5-hydroxyhexyl)phthalate; MEHP: Mono(2-ethylhexyl)phthalate; MDI: Mono(2-ethyl-5-octyl)phthalate; PBDE: Polybrominated diphenyl ether; PCB-153: Polychlorinated biphenyl-153; PFAAs: Perfluorinated alky acids; PFDA: Perfluorooctanoic acid; PFOS: Perfluorooctanesulfonic acid; T3: 3,5,3′-triiodothyronine; T4: Thyroxine; TH: Thyroid hormones; TSH: Thyroid stimulating hormone.

Competing interests
The authors declare that they have no competing interests.

Authors’ contributions
MdB: Ms. DC designed the study, collected the data, carried out the analysis, drafted the initial manuscript, revised the manuscript, and approved the final manuscript as submitted. MdB: Dr. DB carried out the analysis of the data, reviewed and revised the manuscript, and approved the final manuscript as submitted. MdC: Ms. DC designed the study, collected the data, carried out the analysis, revised the manuscript, and approved the final manuscript as submitted. ML: Dr. L supervised the analysis of the biological samples, reviewed and revised the manuscript, and approved the final manuscript as submitted. All authors read and approved the final manuscript.

Acknowledgements
We would like to thank Jacco Koekkoek for the analysis of the samples. This research was funded by the European Community’s Seventh Framework Programme [FP7/2007-2013] under grant agreement OBEUW n° 227391.

Author details
1VU University, Section Health and Life Sciences, Faculty of Earth and Life Sciences, De Boelelaan 1085, 1081HV Amsterdam, The Netherlands. “Institute for Environmental Studies, VU University, Faculty of Earth and Life Sciences, De Boelelaan 1085, 1081HV Amsterdam, The Netherlands.

Received: 7 July 2014 Accepted: 26 November 2014
Published: 10 December 2014

References
1. Bernat J. Thyroid hormones and brain development. Vitam Horm 2005, 71:95–122.
2. Patel J, Landers K, Li H, Mortimer RH, Richard K. Thyroid hormones and fetal neurological development. J Endocrinol 2011, 209:1–8. Epub 2011 Jan 2016.
3. Khatriss J, Pulzer F. Thyroid gland development and defects. Best Pract Res Clin Endocrinol Metab 2008, 22:577–75. doi:10.1016/j.beem.2007.1008.1006.
4. Klein RG, Sargent JD, Larsen PR, Waisbren SE, Haddow JE, Mitchell ML. Relation of severity of maternal hypothyroidism to cognitive development of offspring. J Med Screen 2001, 8:18–20.
5. Medici M, Timmermans S, Visser W, de Munck Keizer-Schrama SM, Jaddoe WW, Hoffman A, Hoijkaas H, de Rijke YB, Tiemeier H, Bongers-Schokking JJ, Visser TJ, Peeters RP, Steegers EA. Maternal thyroid hormone parameters during early pregnancy and birth weight: the Generation R Study. J Clin Endocrinol Metab 2013, 98:59–66.
6. Kodavanti PR, Coburn CG, Moser VC, MacPhail RC, Fenton SE, Stoker TE, Rayner JI, Kannan K, Birnbaum LS. Developmental Exposure to a Commercial PBDE Mixture, DE-71: Neurobehavioral, Hormonal, and Reproductive Effects. Toxicol Sci 2010, 116:297–312.
7. Zhou T, Taylor MM, DeVito MJ, Crafton KM. Developmental exposure to brominated diphenyl ethers results in thyroid hormone disruption. Toxicol Sci 2002, 66:105–116.
8. Miller VM, Sanchez-Morrissey S, Brosch KO, Seegal RF. Developmental coexposure to polychlorinated biphenyls and polybrominated diphenyl ethers has additive effects on circulating thyroxine levels in rats. Toxicol Sci 2012, 127:76–83.
9. He P, Wang A, Niu Q, Guo L, Xia T, Chen X. Toxic effect of PBDE-47 on thyroid development, learning, and memory, and the interaction between PBDE-47 and PCB153 that enhances toxicity in rats. Toxicol Sci 2011, 72:279–288. Epub 2010 Oct 14.
10. Kim TH, Lee YJ, Lee E, Kim MS, Kwack SJ, Kim KB, Chung KK, Kang TS, Han SY, Lee J, Kim BM, Kim HS. Effects of gestational exposure to decabromodiphenyl ether on reproductive parameters, thyroid hormone levels, and neuronal development in Sprague–Dawley rats offspring. J Toxicol Environ Health A 2009, 72:1206–1303. doi:10.1080/10739890903120742.
11. Yu WG, Liu W, Jin YH, Liu XH, Wang FQ, Liu L, Nakayama SF. Prenatal and postnatal impact of perfluorooctane sulfonate (PFOS) on rat development: a cross-foster study on chemical burden and thyroid hormone system. Environ Sci Technol 2009, 43:8416–8422. doi:10.1021/es901602d.
12. Lau C, Tribordeaux JR, Hanson RG, Rogers JM, Grey BC, Stanton ME, Butterhoff JL, Stevenson LA. Exposure to perfluorooctane sulfonate during pregnancy in rat and mouse. II: postnatal thyroid hormones and IGF-1 weakly correlate with breast milk levels of PBDEs in Sprague–Dawley rats offsprings. J Toxicol Environ Health A 2009, 72:1206–1303. doi:10.1080/10739890903120742.
13. Zhou T, Taylor MM, DeVito MJ, Crafton KM. Developmental Exposure to a Commercial PBDE Mixture, DE-71: Neurobehavioral, Hormonal, and Reproductive Effects. Toxicol Sci 2010, 116:297–312.
14. Lin SM, Chen FA, Huang YF, Hsing LL, Chen LL, Wu LS, Liu TS, Chang-Chien GP, Chen KC, Chao HR. Negative associations between PBDE levels and thyroid hormones in cord blood. J Int J Hyg Environ Health 2011, 214:115–120. Epub 2010 Nov 2013.
15. Shy CG, Huang HL, Chao HR, Chang-Chien GP. Cord blood levels of thyroid hormones and IGF-1 weakly correlate with breast milk levels of PBDEs in Taiwan. Int J Environ Res Public Health 2012, 9:7435–351. Epub 2011 Nov 2015.
16. Kim S, Choi K, Ji K, Seo J, Kho Y, Park J, Kim S, Park S, Hwang J, Jeon J, Yang H, Giese JP. Trans-placental transfer of thirteen perfluorinated compounds and relations with fetal thyroid hormones. Environ Sci Technol 2011, 45:7465–7472.
associations between prenatal polychlorinated biphenyl (PCB) and polbrominated diphenyl ether (PBDE) and neonatal thyroid hormone levels. Environ Health Perspect 2008, 116:1376–1382. doi:10.1289/ ehp.110783.

23. Kuppens SM, Kooistra L, Wijnen HA, Vader HL, Hasaart TH, Oei SG, Vulsuma T, Pop VJ. Neonatal thyroid screening results are related to gestational maternal thyroid function. Clin Endocrinol 2011, 75:382–387.

24. Herbstman J, Apelberg BJ, Witter FR, Panny S, Goldman LR. Maternal, infant, and delivery factors associated with neonatal thyroid hormone status. Thyroid 2008, 18:67–76. 10.1089/thy.2007.0180.

25. Pop VJ, Biondi B, Wijnen HA, Kuppens SM, Lvaeder H: Maternal thyroid parameters. Body Mass Index and subsequent weight gain during pregnancy in healthy euthyroid women. Clin Endocrinol 2013, 12:12177.

26. IBM. IBM SPSS Statistics for Windows. 200th edition. Armonk, NY: IBM Corp; 2011.

27. Govarts E, Nieuwenhuijsen M, Schoeters G, Ballister F, Bloemen K, de Boer M, Cheverrie C, Eggisbo M, Guexens M, Kramer U, Legler J, Martinez D, Paklovicova L, Pataraeo E, Rantt U, Rautio A, Petersen M, Slama R, Stigum H, Toft G, Tmocvic T, Vandezentoren M, Welpe P, Kupers NW, Wilhelm M, Witsiwpaj J, Bojde J. Birth weight and prenatal exposure to polychlorinated biphenyls (PCBs) and dichlorodiphenylchloroethylene (DDE): a meta-analysis within 12 European Birth Cohorts. Environ Res 2012, 120:162–170. 10.1016/j.envres.2011.05.012.

28. Maerovet J, Vermeer G, Gocov A, Van Larebeke N, Koppens G, Schoeters G, Nelen V, Baeyens W, Schepens P, Vlaene MK. Association of thyroid hormone concentrations with levels of organochlorine compounds in cord blood of neonates. Environ Health Perspect 2007, 115:783–1796.

29. Asawasinsopon R, Prapamontol T, Prakobvitayakit O, Vaneesorn Y, Mangklabruks A, Hock B. The association between organochlorine and thyroid hormone levels in cord serum: a study from northern Thailand. Environ Int 2006, 32:554–559.

30. Tebourbi O, Hallegue D, Yacoubi MT, Sakly M, Rhouma KB: Competitive binding of poly- and perfluorinated compounds (PFOS) and perfluorooctanoate (PFOA) in relation to weight and size at hepatic enzymes. Environ Int 2008, 33:714–718.

31. Liu C, Shi Y, Li H, Wang Y, Yang K, p-oDDE disturbs the homeostasis of thyroid hormones via thyroid hormone receptors, transthyretin, and hepatic enzymes. Horm Metab Res 2011; 43:391–396.

32. Apelberg BJ, Witter FR, Herbstman JB, Calafat AM, Halden RU, Needham LL, Goldman LR. Cord serum concentrations of perfluorooctane sulfonate (PFOS) and perfluorooctanoate (PFOA) in relation to weight and size at birth. [see comment]. Environ Health Perspect 2007, 115:1670–1676.

33. Chen MH, Ha EH, Wen TW, Su YN, Lien GW, Chen CY, Chen PC, Hsieh WS. Perfluorinated compounds in umbilical cord blood and adverse birth outcomes. PLoS One 2012, 7:3.

34. Lee YJ, Kim MK, Bae J, Yang JH. Concentrations of perfluoroketyl compounds in maternal and umbilical cord sera and birth outcomes in Korea. Chemosphere 2013, 90:1603–1609.

35. Knox SS, Jackson T, Fritsbe SJ, Jawins B, Ducatman AM. Perfluorocarbon exposure, gender and thyroid function in the CB Health Project J. Toxicol Sci 2011, 36:403–410.

36. Alvarez-Pedrerol M, Ribas-Fito N, Torrent M, Juvela J, Ferrer C, Sunyer J. TSH concentration within the normal range is associated with cognitive function and ADHD symptoms in healthy preschoolers. Clin Endocrinol (Oxf) 2007, 66:890–898.

37. Hauser P, Soler R, Brucker-Davis F, Weintrab BD. Thyroid hormones correlate with symptoms of hyperactivity but not inattention in attention deficit hyperactivity disorder. Psychoneuroendocrinology 1997, 22:107–114.

38. RhM: Draaiwerk neonatale hulpinspectie versie 9.1.; 2014.

39. Jones PD, Hu W, De Coen W, Nevestee JT, Gery JP. Binding of perfluorinated fatty acids to serum proteins, Environ Toxicol Chem 2003, 22:2639–2649.

40. Luo Z, Shi X, Hu Q, Zhao B, Huang M. Structural evidence of perfluorooctane sulfonate transport by human serum albumin. Chem Res Toxicol 2012, 25:990–992.

41. Salvalaglio M, Muscinichio L, Cavallotti C. Determination of energies and sites of binding of PFOS and PFOs to human serum albumin. J Phys Chem B 2010, 114:14860–14874.

42. Weiss JM, Andresson PL, Lamoree MH, Leonards PE, van Leeuwen SP, Hammers T. Competitive binding of poly- and perfluorinated compounds to the thyroid hormone transport protein transthyretin. Toxicol Sci 2009, 109:206–216.

43. Nilsson R. Endocrine modulators in the food chain and environment. Toxicol Pathol 2000, 28:420–431.